BioLineRx Stock Forecast, Price & News

-0.01 (-0.31 %)
(As of 07/30/2021 12:56 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume4,345 shs
Average Volume3.45 million shs
Market Capitalization$153.52 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BioLineRx logo

About BioLineRx

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.59 out of 5 stars

Medical Sector

865th out of 2,216 stocks

Pharmaceutical Preparations Industry

421st out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BioLineRx (NASDAQ:BLRX) Frequently Asked Questions

Is BioLineRx a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioLineRx stock.
View analyst ratings for BioLineRx
or view top-rated stocks.

What stocks does MarketBeat like better than BioLineRx?

Wall Street analysts have given BioLineRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioLineRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BioLineRx?

BioLineRx saw a drop in short interest in July. As of July 15th, there was short interest totaling 81,800 shares, a drop of 27.2% from the June 30th total of 112,300 shares. Based on an average trading volume of 5,620,000 shares, the days-to-cover ratio is presently 0.0 days.
View BioLineRx's Short Interest

When is BioLineRx's next earnings date?

BioLineRx is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BioLineRx

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings data on Wednesday, May, 26th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.12.
View BioLineRx's earnings history

How has BioLineRx's stock price been impacted by Coronavirus (COVID-19)?

BioLineRx's stock was trading at $1.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLRX shares have increased by 103.1% and is now trading at $3.25.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BLRX?

2 brokers have issued 12 month target prices for BioLineRx's shares. Their forecasts range from $10.00 to $19.00. On average, they anticipate BioLineRx's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 346.2% from the stock's current price.
View analysts' price targets for BioLineRx
or view top-rated stocks among Wall Street analysts.

Who are BioLineRx's key executives?

BioLineRx's management team includes the following people:
  • Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA, Chief Exec. Officer (Age 61, Pay $555k)
  • Ms. Mali Zeevi CPA, CPA, Chief Financial Officer (Age 45, Pay $314k)
  • Dr. Ella Sorani, Chief Devel. Officer (Age 53, Pay $357k)
  • Dr. Abi Vainstein-Haras, Chief Medical Officer (Age 46, Pay $347k)
  • Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 69)
  • Ms. Liron Shemesh-Darvish M.B.A., Ph.D., Sr. Director & Head of Preclinical Devel.
  • Ms. Jael Birenberg M.Sc., Sr. Director & Head of RA, QA and PhV
  • Ms. Tsipi Keren-Lehrer B.Sc., L.L.B., Head of BD & Strategic Advisor
  • Mr. Raziel Fried, Treasurer & Budgetary Control Director
  • Dr. Leah N Klapper, Consultant (Age 56)

Who are some of BioLineRx's key competitors?

What other stocks do shareholders of BioLineRx own?

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

How do I buy shares of BioLineRx?

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $3.25.

How much money does BioLineRx make?

BioLineRx has a market capitalization of $153.52 million. The biotechnology company earns $-30,020,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does BioLineRx have?

BioLineRx employs 38 workers across the globe.

What is BioLineRx's official website?

The official website for BioLineRx is

Where are BioLineRx's headquarters?

BioLineRx is headquartered at 2 HAMA-AYAN STREET, MODI-IN L3, 7177871.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.